Abstract TMIM-077: MYXOMA VIRUS ENHANCES TREATMENT BENEFIT OF CHEMOTHERAPY AND DENDRITIC CELL IMMUNOTHERAPY IN OVARIAN CANCER PRECLINICAL MODEL

2019 ◽  
Author(s):  
Steven J Conrad ◽  
Bernice Nounamo ◽  
Martin Cannon ◽  
Jia Liu
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cell ◽  
Myxoma Virus ◽  
Preclinical Model ◽  
Treatment Benefit ◽  
Cell Immunotherapy

Understanding dendritic cell immunotherapy in ovarian cancer

2016 ◽  
Vol 16 (6) ◽  
pp. 643-652 ◽  
Author(s):  
Maureen L. Drakes ◽  
Patrick J. Stiff
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cell ◽  
Cell Immunotherapy

Dendritic cell immunotherapy in ovarian cancer

2013 ◽  
Vol 13 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Patrick J Stiff ◽  
Cheryl Czerlanis ◽  
Maureen L Drakes
Keyword(s):  
Ovarian Cancer ◽  
Dendritic Cell ◽  
Cell Immunotherapy

scholarly journals In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity

2019 ◽  
Vol 12 (8) ◽  
pp. 1045-1055 ◽  
Author(s):  
Lucia D'Antona ◽  
Vincenzo Dattilo ◽  
Giada Catalogna ◽  
Domenica Scumaci ◽  
Claudia Vincenza Fiumara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Sensitivity ◽  
Preclinical Model ◽  
Paclitaxel Resistance
Sign in / Sign up

Export Citation Format

Share Document